26.09.2012 - The Berlin-based epigenetics specialist Epigenomics AG has changed its CEO with immediate effect.
Thomas Taapken, formerly CFO will replace his boss Geert Nygaard who will leave the company on September 30. “On behalf of the Board of Directors, I would like to thank Geert Nygaard for his dedication to the Company for the past five and half years", said Heino von Prondzynski, Epigenomics’ Chairman of the Board. Prodzynski, a former Head of Roche Diagnostics, joined the company's board in March this year. He is regarded as a renowned industry expert. Epigenomics has faced several changes in the company's business strategy in the recent years. One year ago, the Berlin-based diagnostics specialist halved its workforce to about 40 staff in the light of a corporate restructuring. Among other things, Epigenomics stopped its own marketing for the Epiprocolon blood test to detect colon cancer in Germany. The focus of the company was turned to the US market where the company runs a clinical study as the basis for a possible FDA approval. The underlying Septin9 marker was out-licensed non-exclusively to a number of partners. However, revenues from this operation do not compensate for the company's development spending. At the end of the second quarter, Epigenomics had €9.1m in cash with a loss of about €5.7m in the first half of 2012.
01.12.2015 Almirall is strengthening its dermatology focus with the takeover of Poli Group. Part of the deal are the group’s two pharma companies, German Taurus Pharma GmbH and Swiss Polichem S.A., and Italian Polichem S.r.l., which produces plastics additives.
26.11.2015 Bioeconomy movers and shakers from every corner of the globe met this week at the world’s first Global Bioeconomy Summit in Berlin to discuss, debate and define better ways to ensure the bioeconomy succeeds on an international level.
24.11.2015 After weeks of speculation it is official: US pharma major Pfizer and Irish Botox maker Allergan will merge. With the deal, Pfizer is planning to dodge the high US taxes, causing indignation among US politicians.
23.11.2015 Amidst talk of the IPO window closing and cancelled flotations, diagnostics firms are still striking a chord with investors. Swedish Immunovia and German Curetis are successfully raising public money.
17.11.2015 The first Italian accelerator specifically for biotech projects has been launched with help from Sofinnova Partners. The plan of BiovelocITA: to help Italy grow into one of Europe’s strongest biotech markets.
13.11.2015 Scientists in Bath, UK, have developed a medical dressing that turns fluorescent green when it detects infection. The researchers hope that the smart burns dressing will help fight antibiotic resistance.
13.11.2015 Out with the old: Roche is discarding four sites with 1,200 staff in an effort to restructure its manufacturing network for small molecules. Instead, a new manufacturing site will be built in Switzerland.
10.11.2015 Algae have many skills, but cancer fighting was not one of them – until now. Researchers from Australia and Germany have genetically engineered diatom algae to accurately deliver chemotherapeutic drugs.